Alpha-3 beta-2 and alpha-7 nicotinic acetylcholine receptors (nAChR) (α3β2 and α7 nAChR)

The alpha-3 beta-2 (α3β2) and alpha-7 (α7) nicotinic acetylcholine receptors (nAChRs) are subtypes of pentameric ligand-gated ion channels that facilitate fast excitatory neurotransmission in the central and peripheral nervous systems (UniProt: P32297, P30532, P36544). The α3β2 subtype is primarily located in autonomic ganglia and specific brain regions, contributing to the autonomic and rewarding effects of nicotine (Arias, 2009). The α7 receptor is a homopentameric channel with high calcium permeability, playing a critical role in cognitive functions, sensory gating, and neuroprotection (PubMed: 10903440). Bupropion, an antidepressant and smoking cessation aid, acts as a non-competitive antagonist at these receptors, effectively blocking the ion channel pore to inhibit the effects of nicotine (Slemmer et al., 2000). This antagonism is thought to reduce the reinforcing properties of tobacco use and alleviate withdrawal symptoms. Clinically, these receptors are targets for treating nicotine addiction, schizophrenia, and cognitive deficits associated with Alzheimer's disease (NIH: StatPearls). Dysregulation of these cholinergic pathways is also implicated in major depressive disorder and inflammatory conditions, making them significant therapeutic targets. Therapeutic modulation of these receptors requires careful management due to their widespread expression and involvement in vital autonomic functions.

Other names

CHRNA3/CHRNB2 complexCHRNA7Neuronal nicotinic acetylcholine receptor alpha-3 beta-2Neuronal nicotinic acetylcholine receptor alpha-7Cholinergic receptor nicotinic alpha 3 subunitCholinergic receptor nicotinic beta 2 subunitCholinergic receptor nicotinic alpha 7 subunit

Non-competitive antagonism and channel pore blockade of the nicotinic acetylcholine receptors.